• Founded: 2014
  • Location: Montréal, QC
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Hematologic malignancies
  • Drug types: ONC, X_X
  • Lead product: ECT-001-CB
  • Product link: https://excellthera.com/pipeline/
  • Funding: <10M



job board

Short description:

Growing blood stem cells for therapeutic use

Drug notes:

4 undisclosed programs Clin0 organ transplant, undisclosed

Long description:

ExCellThera is developing stem cell therapies to engineer various cell lines for hematological malignancies. Thousands of patients in need of stem cell transplants are in need of a donor and those that do get one, do not always respond. ExCellThera is addressing this problem through the development of novel, one-time curative cell therapies based on their proprietary UM171 technology. UM171 is a molecule with hematopoeitic stem cell expansion properties which can be used to expand the low number of stem cells found in cord blood. ExCellThera’s lead candidate cell therapy, ECT-001, is composed of UM171-expanded stem cells to treat blood diseases. Initial Phase I/II clinical trials have already been completed with promising results.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com